首页> 中文期刊> 《中华骨质疏松和骨矿盐疾病杂志》 >骨纤维异常增殖症的发病机制及药物治疗

骨纤维异常增殖症的发病机制及药物治疗

         

摘要

Fibrous dysplasia of bone is a skeletal disease caused by somatic activating mutations of the Gsa . The mutation results in osteoblastic differentiation defects and increased bone resorption .Hypophosphatemic osteomalacia has been reported as a rare complication of FD .Patients with polyostotic fibrous dysplasia often have renal phosphate wast-ing.New insight into the molecular mechanisms has led to the use of antiresorptive agent for treatment of FD .Favorable outcomes have been observed in some open studies using intravenous or oral bisphosphonates and denosumab .Further clinical evaluation is needed .Calcium, vitamin D and phosphorus supplements are probably helpful in patients with FD to limit osteomalacic and hyperparathyroid changes , which are likely to influence the severity of FD .%骨纤维异常增殖症( FD)是由G蛋白ɑ亚基基因突变引起的一种代谢性骨病。成骨细胞分化异常及破骨细胞活性增强的双重因素参与FD发病机制,少数患者伴低磷性骨软化症,加重FD骨骼病变。近年基于发病机制的药物治疗逐渐受到重视,其中骨吸收抑制剂———双膦酸盐和抗 RANKL单克隆抗体已在部分临床研究中取得良好疗效,但仍需进一步研究证实。另外,钙剂、维生素D可作为FD患者的补充治疗,合并低磷血症患者可酌情补充磷制剂。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号